Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days

Table 3 Changes in quality of life measured with the MIDAS after 90 days and 180 days contraception with desogestrel 75 μg

N = 42	Mean (SD) Baseline	Mean (SD) TP 1	Mean (SD) TP 2	Overall p-value	P-value baseline vs. TP1	*Posthoc P-value baseline vs. TP2**	P-value TP1 vs. TP2
MIDAS SCORE	36.3 (41.9)	18.3 (38.8)	16.0 (32.8)	<0.001	<0.001	<0.001	0.176
MIDAS 1: days missed at work	7.0 (15.2)	3.8 (13.6)	2.6 (10.9)	<0.001	<0.001	0.002	0.093
MIDAS 2: days with >50% reduced productivity at work	7.6 (5.4)	4.2 (4.6)	3.9 (4.9)	0.001	0.002	0.001	0.650
MIDAS 3: days without household work	6.3 (9.7)	3.6 (8.1)	2.6 (4.4)	<0.001	0.002	<0.001	0.161
MIDAS 4: days with >50% reduced productivity in household work	5.8 (6.8)	3.9 (7.0)	3.9 (8.2)	0.006	<0.009	0.046	0.766
MIDAS 5: days when family, social or leisure activities are missed	9.8 (15.3)	3.7 (9.9)	3.1 (7.2)	<0.001	<0.001	<0.001	0.481
MIDAS: Headache days	26.4 (19.3)	17.0 (15.5)	17.0 (18.1)	<0.001	0.002	<0.001	0.487
MIDAS: Pain intensity (scale 0–10)	6.1 (1.7)	4.8 (1.5)	4.5 (2.0)	<0.001	<0.001	<0.001	0.078
MIDAS: Grade	3.6 (0.7)	2.4 (1.0)	2.2 (1.2)	<0.001	<0.001	<0.001	0.295

Baseline: before treatment, TP1: 1–90 days use of desogestrel; TP2: 91–180 days desogestrel use.
*after Bonferroni correction, post-hoc p-values are significant at p < 0.017.

ISSN: 1129-2377